November 29, 2020 Uncategorized

GE Healthcare Expands AI, Digital and Imaging Solutions at #RSNA20, Helping Shape Future of Healthcare in the COVID Era

CHICAGO – 29 NOVEMBER 2020 –GE Healthcare today unveiled a slate of new intelligently efficient solutions to help clinicians solve today’s two-part challenge of delivering high quality care while managing greater capacity and workflow issues, exacerbated by the impact of COVID-19. Building on continuing investments in innovation and digital health momentum, GE Healthcare is expanding... Read more

November 23, 2020 Uncategorized

GE Healthcare Announces First X-ray AI to Help Assess Endotracheal Tube Placement for COVID-19 Patients

Critical Care Suite 2.0 helps clinicians assess Endotracheal Tube (ETT) placement for intubated patients, including critical COVID-19 patients New AI suite includes algorithms that help radiologists prioritize critical cases and automate processes to help cut average review time from up to eight https://www.ge.com/news/press-releases/ge-healthcare-announces-first-x-ray-ai-to-help-assess-endotracheal-tube-placement-0 Read more

November 20, 2020 Uncategorized

GE Healthcare Pioneers Photon Counting CT with Prismatic Sensors Acquisition

GE Healthcare invests in a unique approach to cutting-edge CT technology and acquires Prismatic Sensors AB, a leader in Deep Silicon detector technology for photon counting computed tomography (PCCT) CHICAGO, November 20, 2020 – GE Healthcare today announced its acquisition of Prismatic Sensors AB https://www.ge.com/news/press-releases/ge-healthcare-pioneers-photon-counting-ct-with-prismatic-sensors-acquisition Read more

November 18, 2020 Uncategorized

WITec Headquarters Expansion Update

We’ve produced aerial drone footage of our headquarters expansion that shows the current state of its construction. The work is progressing steadily and the scale of the addition that will double capacity at our core facility is clearly visible. We look forward to the new spaces for production, development, shipping, product demonstrations and many other... Read more

November 13, 2020 Uncategorized

CHMP recommends EU approval of Roche’s Xofluza® (baloxavir marboxil) for the treatment of influenza

One-dose, oral Xofluza has been recommended for approval for the treatment of uncomplicated influenza in patients aged 12 years and above Xofluza has also been recommended for approval as a preventive treatment (post-exposure prophylaxis) of influenza in individuals aged 12 years and above If approved, Xofluza would be the first innovation in mode of action... Read more

November 13, 2020 Uncategorized

CHMP recommends EU approval of Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer

Phesgo offers faster and less invasive delivery of standard of care treatment with Perjeta and Herceptin, under the skin in just minutes, compared to hours with intravenous infusion1,2,3 Subcutaneous administration is preferred by patients, physicians and healthcare providers, and can be associated with reduced hospital times and costs4,5,6 This is the first time that Roche... Read more

November 12, 2020 Uncategorized

Takara Bio Report 2020

Home Corporate Guide Message from the president Corporate Data Corporate History Corporate Executives Directions to Takara Bio Sustainability Initiatives Business Outline News Release Investor Relstions Management Policy Financial Data IR Library Stock Information IR Calendar IR News Disclosure Policy FAQ Contact IR User Guide Products Site About Us Business Outline News Release Investor Relations Japanese... Read more

November 11, 2020 Uncategorized

QIAGEN announces start of share repurchase for up to $100 million

Venlo, the Netherlands, November 11, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has commenced a share repurchase of up to $100 million as authorized in a repurchase program already announced on May 6, 2019. In the period between today and December 17, 2020, at the latest, up to $100 million of... Read more

November 2, 2020 Uncategorized

European Commission approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer

Basel, 2 November 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. “Tecentriq in combination with Avastin is the first treatment... Read more